Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Saglik Bilimlerinde Ileri Arastirmalar Dergisi / Journal of Advanced Research in Health Sciences ; 4(1 Suppl):S83-S95, 2021.
Article in Turkish | CAB Abstracts | ID: covidwho-1876447


The COVID-19 pandemic causes an increase in oral health inequalities, restriction of oral health promotion programs and preventive oral health services for the community. According to the common risk approach, oral health services should be integrated into primary health care services in order to manage oral diseases that share the same risk factors with chronic systemic diseases. Multidisciplinary studies should be focused on public health practices by adopting the "One Health" concept. In order to increase the popuation based oral health outcomes, there is a need for oral health promotion programs that take into account the cooperation between sectors, working flexibility, capacity, the ethical rules of social justice, equality and human rights within the framework of the biopsychosocial approach. Information technologies and social media networks should be used to increase the literacy of the population on "COVID-19 and Oral Health". In this period, it is also important to carry out oral health needs assessment at population level through surveillance and public health studies. Priority should be given to programs for the protection and improvement of oral health among disadvantaged groups, children and the elderly who have difficulty in accessing oral health services due to limitation of movement and social determinants of health.

Pharmaceuticals ; 14(4):19, 2021.
Article in English | MEDLINE | ID: covidwho-1209746


To date, the leading causes of mortality and morbidity worldwide include viral infections, such as Ebola, influenza virus, acquired immunodeficiency syndrome (AIDS), severe acute respiratory syndrome (SARS) and recently COVID-19 disease, caused by the SARS-CoV-2 virus. Currently, we can count on a narrow range of antiviral drugs, especially older generation ones like ribavirin and interferon which are effective against viruses in vitro but can often be ineffective in patients. In addition to these, we have antiviral agents for the treatment of herpes virus, influenza virus, HIV and hepatitis virus. Recently, drugs used in the past especially against ebolavirus, such as remdesivir and favipiravir, have been considered for the treatment of COVID-19 disease. However, even if these drugs represent important tools against viral diseases, they are certainly not sufficient to defend us from the multitude of viruses present in the environment. This represents a huge problem, especially considering the unprecedented global threat due to the advancement of COVID-19, which represents a potential risk to the health and life of millions of people. The demand, therefore, for new and effective antiviral drugs is very high. This review focuses on three fundamental points: (1) presents the main threats to human health, reviewing the most widespread viral diseases in the world, thus describing the scenario caused by the disease in question each time and evaluating the specific therapeutic remedies currently available. (2) It comprehensively describes main phytochemical classes, in particular from plant foods, with proven antiviral activities, the viruses potentially treated with the described phytochemicals. (3) Consideration of the various applications of drug delivery systems in order to improve the bioavailability of these compounds or extracts. A PRISMA flow diagram was used for the inclusion of the works. Taking into consideration the recent dramatic events caused by COVID-19 pandemic, the cry of alarm that denounces critical need for new antiviral drugs is extremely strong. For these reasons, a continuous systematic exploration of plant foods and their phytochemicals is necessary for the development of new antiviral agents capable of saving lives and improving their well-being.

Annals of Clinical and Laboratory Science ; 50(6):848-851, 2020.
Article in English | Web of Science | ID: covidwho-1001036


Objective. To investigate the course of biomarkers on admission and follow-up in order to identify early predictors for poor outcome in COVID-19 patients. Methods. In this study, 132 COVID-19 patients were classified as good outcome (n=62) and poor outcome (n=70) groups. Laboratory parameters were evaluated on admission and within 5-7 days after hospitalization. Results. Baseline levels of neutrophil-lymphocyte ratio, CRP, procalcitonin, ferritin, D-dimer and LDH were higher (p<0.01);lymphocyte count was lower in the poor outcome patients. During follow-up there was a larger decrease in lymphocyte count and more prominent increases in other biomarkers (p<0.001). In ROC analysis, the AUCs strongly indicated the poor outcome on days 5-7 of the hospitalization. Conclusions. This study suggests that the follow-up measurements of the biomarkers better predict the poor outcome in COVID-19 pneumonia.